此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

2019年7月22日 更新者:Chipscreen Biosciences, Ltd.

Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study

Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B(Aurora B)、VEGFR/PDGFR/c-Kit、CSF-1R targets.

This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.

研究概览

地位

终止

研究类型

介入性

注册 (实际的)

5

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing
      • Beijing、Beijing、中国、100021
        • Cancer Hospital, Chinese Academy of Medical Sciences

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Male or Female, aged ≥ 18 yrs and ≤70 yrs;
  2. Histological or cytological confirmation of non-Hodgkin's lymphoma(NHL), including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other aggressive NHLs which determined by the investigator.
  3. Patients with NHL refractory to at least 2 different chemotherapies , for which no standard therapy exists;
  4. At least 1 lesion can be accurately measured, as defined by Lugano 2014 criteria.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
  6. Subjects received anti-cancer therapy (including chemotherapy, radiotherapy, immunotherapy and surgical therapy, et al) should beyond 4 weeks prior to study entry; Subjects received mitomycin chemotherapy should beyond 6 weeks prior to study entry; Subjects received autologous stem cell transplantation should beyond 3 months prior to study entry;
  7. Laboratory criteria are as follows:

    Complete blood count: hemoglobin (Hb) ≥90g/L ; absolute neutrophil count (ANC) ≥1.5×109/L ; platelets >=90×109/L Biochemistry test: total bilirubin≦1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≦1.5×ULN; (ALT,AST≦5×ULN if liver involved) ;serum creatinine(cr)≦1.5×ULN; Coagulation test: International Normalized Ratio (INR) < 1.5

  8. Life expectancy of at least 12 weeks.
  9. Willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Patients with prior invasive malignancies with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, unless received curative treatment and with documented evidence of no recurrence in the past five years;
  2. Clinical evidence of central nervous system involvement;
  3. Have uncontrolled or significant cardiovascular disease, including:

    1. Congestive heart failure, unstable angina pectoris, myocardial infarction within 6 months prior to study entry; arrhythmia, or Left Ventricular Ejection Fraction (LVEF) < 50% requiring treatment with agents during screening stage.
    2. primary cardiomyopathy(dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al)
    3. History of significant QT interval prolongation, or Corrected QT Interval (QTc) > 450 ms prior to study entry
    4. Symptomatic coronary heart disease requiring treatment with agents
    5. Uncontrolled hypertension (> 140/90 mmHg) by single agent;
  4. Have active bleeding current thrombotic disease, patients with bleeding potential ,or receiving anticoagulation therapy; within 2 months prior to screening;
  5. Proteinuria positive(≥1g/24h);
  6. History of deep vein thrombosis or pulmonary embolism;
  7. Have unsolved toxicities (> grade 1) from prior anti-cancer therapy;
  8. Have clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, that would impair the ingestion,transportation or absorption of oral agents, or patients undergone gastrectomy;
  9. History of organ transplantation or Allogeneic bone marrow transplantation;
  10. Major surgery within 6 weeks and minor surgery within 2 weeks prior to screening (excluding placement of vascular access or biopsy) that involved general anaesthesia or respiratory assistance;
  11. Serologically positive for HIV, hepatitis B or C, or other serious infectious diseases;
  12. History of interstitial lung disease(ILD);
  13. Previous treatment with aurora kinase inhibitors;
  14. Patients appropriate and ready for autologous stem cell transplantation;
  15. Any mental or cognitive disorder, that would impair the ability to understand the informed consent document or the operation and compliance of study;
  16. Candidate with drug and alcohol abuse;
  17. Participants of reproductive potential not willing to use adequate contraceptive measures for the duration of the study (both male and female participants).Pregnant or breastfeeding women. Female participants must have a negative urinary or serum pregnancy test when done or have evidence of post-menopausal status (Defined as absence of menstruation for greater than 12 months, bilateral oophorectomy or hysterectomy);
  18. Any other condition which is inappropriate for the study in the opinion of the investigators.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:基奥拉尼
患者服用 Chiauranib 胶囊 50mg,口服,每日 1 次,28 天为一个周期。
每天口服一次 50mg
其他名称:
  • CS2164

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
总缓解率(ORR)
大体时间:评估长达2年
ORR 将根据末次访视获得的数据计算
评估长达2年

次要结果测量

结果测量
措施说明
大体时间
缓解持续时间 (DOR)
大体时间:评估长达2年
从反应的第一个日期到第一个记录的进展日期
评估长达2年
Number of participants with treatment-related adverse events
大体时间:Measured through 2 years
measured by adverse events (AE), serious adverse events (SAE), abnormal vital signs,electrocardiograph(ECG) and abnormal laboratory results according to CTCAE V4.03
Measured through 2 years
progression-free survival (PFS)
大体时间:assessed up to 2 years
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first
assessed up to 2 years
time to progression(TTP)
大体时间:through treatment completion, up to 2 years
duration from date of treatment until the date of first documented progression
through treatment completion, up to 2 years
complete remission rate(CRR)
大体时间:through treatment completion, up to 2 years
through treatment completion, up to 2 years
overall survival(OS)
大体时间:assessed up to 2 years
Time from treatment to death from any cause
assessed up to 2 years

其他结果措施

结果测量
措施说明
大体时间
Aurora B、CSF-1R和Myc蛋白的免疫组化(IHC)染色结果
大体时间:评估长达2年
IHC 染色结果的平均值如下:0,阴性; 1、虚弱; 2、适中; 3、强。 阳性细胞频率定义如下:0,小于5%; 1、5%~25%; 2、26%~50%; 3、51%~75%; 4、大于75%。
评估长达2年
CtDNA中癌基因的任何单一突变和拷贝数变异(单基因分析)
大体时间:评估长达2年
评估长达2年
信号通路中的多基因突变和拷贝数变异(多基因分析)
大体时间:评估长达2年
评估长达2年

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年5月9日

初级完成 (实际的)

2017年8月15日

研究完成 (实际的)

2019年2月14日

研究注册日期

首次提交

2017年3月1日

首先提交符合 QC 标准的

2017年3月5日

首次发布 (实际的)

2017年3月9日

研究记录更新

最后更新发布 (实际的)

2019年7月24日

上次提交的符合 QC 标准的更新

2019年7月22日

最后验证

2019年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅